MetaCap

Fulcrum Therapeutics (FULC) vs ARS Pharmaceuticals (SPRY)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

ARS Pharmaceuticals (SPRY) has outperformed Fulcrum Therapeutics (FULC) over the past year, losing 61.0% versus a loss of 67.3%. Over five years, SPRY leads with a -58.8% price change compared with -75.5% for FULC. ARS Pharmaceuticals is the larger company by market cap ($297.6 million vs $281.8 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

FULC-67.32%SPRY-61.00%
+79%-0%-79%
Nov 21, 20251 yearNov 20, 2026
FULC-78.47%SPRY-63.99%
+132%+18%-96%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

FULC versus SPRY key metrics
MetricFULCSPRY
Share price$3.69$2.96
Market cap$281.85M$297.56M
1-day change-0.54%-11.90%
YTD return-67.37%-74.59%
1-year return-67.32%-61.00%
5-year return-75.50%-58.83%
EPS (TTM)$-1.04$-2.01
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$84.28M
Revenue growth (YoY)-100.00%-5.46%
Net income (latest FY)$-74.88M$-171.30M
Operating margin—-212.92%
Net margin—-203.25%
52-week high$15.74$13.15
52-week low$2.83$2.44
Distance from 52-week high-76.56%-77.49%
Analyst consensusholdstrong_buy
Avg. price target upside-0.54%+474.32%
Average volume1.37M1.83M
Shares outstanding76.38M100.53M
Employees55203
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ARS Pharmaceuticals grew revenue faster in its latest fiscal year (-5.46% vs -100.00%).

About Fulcrum Therapeutics

FULC stock →

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia.

Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees

About ARS Pharmaceuticals

SPRY stock →

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis.

Health Care · Biotechnology: Pharmaceutical Preparations · 203 employees

FULC vs SPRY FAQ

Which is bigger, Fulcrum Therapeutics or ARS Pharmaceuticals?

ARS Pharmaceuticals (SPRY) is larger, with a market capitalization of $297.56M compared with $281.85M for Fulcrum Therapeutics (FULC).

Which stock has performed better over the past year, FULC or SPRY?

SPRY returned -61.00% over the past 12 months, compared with -67.32% for FULC (price return, excluding dividends). Past performance does not predict future results.

Are Fulcrum Therapeutics and ARS Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons